ShangPharma and Qidong Biopharma Industrial Zone sign an agreement for a $60-million investment in China
The plans include a multifunctional preclinical research facility and a state-of-the-art biologics manufacturing facility.
ShangPharma has announced plans to establish a subsidiary in the Qidong Biopharma Industrial Zone as part of a multistage expansion project for its biologics service portfolio. In the first phase, ShangPharma and Qidong Biopharma Industrial zone will invest 60 million USD to build a comprehensive and multifunctional preclinical research facility, as well as a state-of-the-art biologics manufacturing facility. The preclinical facility will be operated by ShangPharma’s CRO division, ChemPartner and the biologics manufacturing facility will be operated by ShangPharma’s CMO division, China Gateway Biologics. During the construction phase of the manufacturing facility, the company’s existing biologics CMC facility will continue to operate out of its Shanghai site.
The new China Gateway Biologics’ manufacturing facility will provide commercial-scale operations for biopharmaceuticals. It will be comprised one 500-L single-use mammalian cell culture train for clinical phase supply and two 2000-L trains for commercial manufacturing. These capabilities will be complemented with fill & finish capabilities of the appropriate scale.
Michael Hui, CEO of ShangPharma stated: “I am proud that Qidong Biopharma Industrial Zone has selected ShangPharma as partner for the first facility of this kind in Qidong. The investment offers China Gateway Biologics the opportunity to grow to the next level as a full biopharmaceutical service provider from preclinical development to commercial scale. We strongly believe the state-of-the-art single-use facility conforming to Western standards will be able to support our international client base.”
Xu Feng, Qidong’s Party Secretary and Chairman of Qidong Standing Committee of the People’s Congress said: “Choosing ShangPharma as the first tenant for the biopharma zone in Qidong is a big milestone to establish Qidong as a biotech hub at the door steps of Shanghai. ShangPharma/CGB is a strong partner with international focus and the facility will serve as model for other projects of similar scale and needs.”
The biopharmaceutical manufacturing facility shall be operational for the first client project in early 2018.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance